碳酸镧治疗维持性透析患者并发高磷血症疗效观察

目的评价碳酸镧治疗维持性透析患者高磷血症的有效性。方法根据是否服用碳酸镧将患者分为观察组和对照组。碳酸镧观察组16例,均服用碳酸镧,每次500 mg,2³次/d;对照组23例,口服碳酸钙,0.75g/次,每天2次。结果与治疗前比较,治疗1、2、6个月后,观察组血磷水平均下降(P<0.01),对照组下降不明显(P>0.05),且观察组较对照组各时点血磷下降明显[(1.80±0.25)mmol/L vs.(2.21±0.33)mmol-/L、(1.56±0.19)mmol儿vs.(2.28±0.26)mmol/L、(1.51±0.17)mmo;/L vs.(2.29±0.25)mmol/L](P<0.01)。2组血钙下降均不明显(P>0.05);治疗6个月后,观察组PTH较对照组下降更明显[(614.8±178.38)pg/ml vs.(982.63±716.34)pg/ml](P<0.05)。结论碳酸镧治疗维持性透析患者高磷血症较传统降磷方法治疗有效。

Lanthanum carbonate treatment of maintenance hemodialysis patients with hyperphosphatemia

Objective To evaluate the effectivenes of lanthanum carbonate for hyperphosphatemia in patients undergoing maintenance hemodialysis. Methods According to whether taking lanthanum carbonate or not, patients were divided into observation group and control group. Lanthanum carbonate observation group of 16 cases, were treated with lanthanum carbonate, every time 500 rag, 2 - 3 times/d; 23 cases in the control group, oral calcium carbonate. 0.75 g,twice aday. Resuits Compared with before treatment, treatment for 1, 2, 6 months later, the observation group serum phosphorus levels were decreased （ P 〈 0.01 ） , the control group decreased not obviously （ P 〉 0.05 ） , and the observation group serum phosphorus decreased significantly [ （ 1.80 ± 0.25 ） mmol/L vs. （2.21 ±0.33 ） retool/L, （ 1.56 ± 0.19） mmol/L vs. （ 2.28 ± 0.26） mmol/L, （1.51 ±0.17） mmol/L vs. （2.29 ±0.25） mmol/L] （ P 〈0.01） than those in the control group. The 2 groups of calcium decreased not significantly（ P 〉 0.05） ; after 6 months of treatment, compared with the control group, the observation group PPTH decreased more significantly [ （614.80 ± 178.38） pg/ml vs. （982.63 ±716.34） pg/ml] （ P 〈 0.05 ）. Conclusion Lanthanum carbonate treatment of maintenance hemodialysis patients with hyperphosphatemia is better than the traditional method is effective in the treatment of phosphorus reduction.